No Data
Hunan Warrant Pharma Completes Phase 2 Trial for Respiratory Traditional Chinese Drug
Warner Pharmaceutical (688799.SH) has received the summary report of the Phase II clinical trial for Qianqing granules.
Warner Pharmaceuticals (688799.SH) announced that the research project Qianqing granules has been approved by the National Medical Products Administration...
Wanah Pharmacy (688799.SH): plans to launch a restricted stocks incentive plan of 3.41 million shares.
Grain News December 4th | Warner Pharma (688799.SH) announced the 2024 restricted stocks incentive plan, with the plan proposing to grant 3.41 million restricted stocks to incentive recipients, accounting for approximately 3.64% of the company's total share capital of 93.8 million shares on the date of the plan announcement. This grant is a one-time grant with no reserved rights.
Warner Pharmaceutical Factory (688799.SH): Xu Xiaoqiang and Xu Yuehan plan to collectively reduce their shareholding by no more than 1.352 million shares.
Gelonghui on December 2nd: Warner Pharmaceutical Factory (688799.SH) announced that shareholders Mr. Xu Xiaoqiang and Ms. Xu Yuehan plan to reduce their shareholdings in the company by a total of no more than 1,352,000 shares due to their own financial needs. Among them, they plan to reduce their shareholdings by no more than 938,000 shares through the trading method, not exceeding 1% of the total share capital of the company; they plan to reduce no more than 1,352,000 shares through block trading, that is, no more than 1.44% of the total share capital of the company.
Hunan Warrant Pharmaceutical Gets Supplementary Drug Approval for Chest Pain Drug
Warner Pharmaceutical (688799.SH): Received the notification of approval for the supplemental pharmaceutical application.
On November 19, Ge Longhui announced that Warner Pharmaceutical Factory (688799.SH) received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration regarding the change of the holder of the marketing authorization for Benidipine Hydrochloride Tablets. Benidipine hydrochloride tablets are suitable for primary hypertension and angina pectoris. The company has become the holder of the marketing authorization for Benidipine hydrochloride tablets, further enriching the company's formulation product variety, which has a positive significance for optimizing the company's product structure.
Hunan Warrant Pharmaceutical Co.,Ltd's (SHSE:688799) Shares Bounce 43% But Its Business Still Trails The Market
